Pricing Log in Create free account

NewAmsterdam Pharma Company N.V. (NAMS) vs Xencor, Inc. (XNCR)

NewAmsterdam Pharma Company N.V. and Xencor, Inc. are both Biotechnology companies. Xencor, Inc. is the larger, with a market value of $2.5B against $2.3B — 1.1× the size. NewAmsterdam Pharma Company N.V. grew revenue faster over the last twelve months: −26.4% against −28.6%. Xencor, Inc. has the higher net margin (−155.6% vs −789.9%) and the lower return on invested capital (−288.7% vs −23.1%). Across the 15 metrics below, Xencor, Inc. leads on 10 and NewAmsterdam Pharma Company N.V. on 5.

Valuation

Metric NAMS XNCR Biotechnology median
P/E n/m n/m 10.26
P/S 91.08 24.80 9.18
P/B 3.75 5.17 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 66.59 21.59 8.98
Earnings yield (8.88%) (6.32%) (34.89%)
Free cash flow yield (6.39%) (8.04%) (24.52%)

Profitability

Metric NAMS XNCR Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (900.07%) (205.84%) 0.00%
Net margin (789.94%) (155.59%) 0.00%
Free cash flow margin (581.64%) (198.42%) 0.00%
Return on equity (30.16%) (29.07%) (50.12%)
Return on assets (27.79%) (20.36%) (45.60%)
Return on invested capital (23.13%) (288.71%) 0.00%

Growth

Metric NAMS XNCR Biotechnology median
Revenue growth (TTM) (26.41%) (28.56%) 6.26%
EPS growth (last fiscal year) 32.81% 65.36% 29.88%
Revenue growth, 5-year CAGR — 0.47% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NAMS XNCR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.76 6.39 4.89
Net debt to EBITDA 2.83 2.51 1.01

Dividend

Metric NAMS XNCR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric NAMS XNCR Biotechnology median
Market cap 2.26b 2.53b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack